AstraZeneca and GSK aim to bring their immunotherapy to the endometrial cancer patient population
AstraZeneca follows BI and caps monthly out-of-pocket inhaler costs at $35
Bristol Myers Squibb's dual immunotherapy combination could potentially prolong the lives of patients with liver cancer
Takeda's treatment indicated for Ph+ALL receives FDA approval as a first-line treatment option
Merck's attempt to combine Lynparza with Keytruda to treat non-small cell lung cancer has failed in trial once again
With several companies investing in obesity drugs, NovoNordisk & Eli Lily may face tough competition in the years to come
J&J taps software company, Nvidia, to help deliver real-time analyses of surgical data
Automated insulin pump receives FDA approval and is ready to support people withType 1 diabetes
Kentucky is the fourth state allowing insurers to encourage use of biosimilars prior to covering the branded equivalent
%402x.svg){kind=icon}
.png)
%402x.svg){kind=icon}
